Genistein Suppresses v-Src-Driven Proliferative Activity by Arresting the Cell-Cycle at G2/M through Increasing p21 Level in Src-Activated Human Gallbladder Carcinoma cells

References

• Krizova L, Dadakova K, Kasparovska J, Kasparovsky T. Isoflavones. Molecules. 2019;24(6):1076. doi:10.3390/molecules24061076
   Web of Science ®Google Scholar
• Hwang K-A, Kang N-H, Yi B-R, Lee H-R, Park M-A, Choi K-C. Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovarian cancer cells induced by induced by 17β-estradiol or bisphenol A via the inhibition of cell cycle progression . Int J Oncol. 2013;42(2):733–740. doi:10.3892/ijo.2012.1719
   PubMed Web of Science ®Google Scholar
• Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010;140(7):1355S–1362S. doi:10.3945/jn.109.119776
   PubMed Web of Science ®Google Scholar
• Uifălean A, Schneider S, Ionescu C, Lalk M, Iuga CA. Soy isoflavones and breast cancer cell lines: molecular mechanisms and future perspectives. Molecules. 2015;21(1):E13. doi:10.3390/molecules21010013
   PubMed Web of Science ®Google Scholar
• Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19(49):5636–5642. doi:10.1038/sj.onc.1203912
   PubMed Web of Science ®Google Scholar
• Jove R, Hanafusa H. Cell transformation by the viral src oncogene. Annu Rev Cell Biol. 1987;3:31–56. doi:10.1146/annurev.cb.03.110187.000335
   PubMedGoogle Scholar
• Tatsumoto T, Nakano S, Shimizu K, Ono M, Esaki T, Ohshima K, Niho Y. Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene. Int J Cancer. 1995;61(2):206–213. doi:10.1002/ijc.2910610211
   PubMed Web of Science ®Google Scholar
• Hisano C, Tanaka R, Fujishima H, Ariyama H, Tsuchiya T. Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells. Cell Biol Int. 2003;27(5):415–421. doi:10.1016/S1065-6995(03)00032-5
   PubMed Web of Science ®Google Scholar
• Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer. 1999;80(5):731–737. doi:10.1002/(sici)1097-0215(19990301)80:5 < 731::aid-ijc17 > 3.0.co;2-h
   PubMed Web of Science ®Google Scholar
• Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol. 2006;58(5):577–584. doi:10.1007/s00280-006-0219-4
   PubMed Web of Science ®Google Scholar
• Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet. 1999;21(2):187–190.:doi:10.1038/5971
   PubMed Web of Science ®Google Scholar
• Jacobs C, Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983;43(4):1696–1702.
   PubMed Web of Science ®Google Scholar
• Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 1992;52(17):4773–4778.
   PubMed Web of Science ®Google Scholar
• Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA. 1987;84(8):2251–2255. doi:10.1073/pnas.84.8.2251
   PubMed Web of Science ®Google Scholar
• Cartwright CA, Meisler AI, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA. 1990;87(2):558–562. doi:10.1073/pnas.87.2.558
   PubMed Web of Science ®Google Scholar
• Fanning P, Bulovas K, Saini KS, Libertino JA, Joyce AD, Summerhayes IC. Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res. 1992;52(6):1457–1462.
   PubMed Web of Science ®Google Scholar
• Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Lührs H, Friess H, Büchler MW, Adler G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun. 1998;243(2):503–508. doi:10.1006/bbrc.1997.8043
   PubMed Web of Science ®Google Scholar
• Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ, et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene. 1997;15(25):3083–3090. doi:10.1038/sj.onc.1201496
   PubMed Web of Science ®Google Scholar
• Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist. 2011;16(5):566–578. doi:10.1634/theoncologist.2010-0408
   PubMed Web of Science ®Google Scholar
• Wang H, Khor TO, Shu L, Su Z-Y, Fuentes F, Lee J-H, Kong A-NT. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem. 2012;12(10):1281–1305. doi:10.2174/187152012803833026
   PubMed Web of Science ®Google Scholar
• Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262(12):5592–5595.
   PubMed Web of Science ®Google Scholar
• Nakano S, Tatsumoto T, Esaki T, Nakamura M, Baba E, Kimura A, Ohshima K, Niho Y. Characterization of a newly established human gallbladder carcinoma cell line. In Vitro Cell Dev Biol Anim. 1994;30A(11):729–732. doi:10.1007/bf02631291
   PubMed Web of Science ®Google Scholar
• Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnica-Worms H. Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell. 1994;5(9):989–1001. doi:10.1091/mbc.5.9.989
   PubMed Web of Science ®Google Scholar
• Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. Embo J. 1991;10(11):3321–3329.
   PubMed Web of Science ®Google Scholar
• Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Yamamoto S, Tsugane S, Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol. 2008;26(10):1677–1683. doi:10.1200/JCO.2007.13.9964
   PubMed Web of Science ®Google Scholar
• Ono M, Ejima K, Higuchi T, Takeshima M, Wakimoto R, Nakano S. Equol enhances apoptosis-inducing activity of genistein by increasing Bax/Bcl-xL expression ratio in MCF-7 human breast cancer cells. Nutr Cancer. 2017;69(8):1300–1307. doi:10.1080/01635581.2017.1367945
   PubMed Web of Science ®Google Scholar
• Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008;10:e19. doi:10.1017/S1462399408000744
   PubMedGoogle Scholar
• El-Deiry WS. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 2016;76(18):5189–5191. doi:10.1158/0008-5472.CAN-16-2055
   PubMed Web of Science ®Google Scholar
• Shao ZM, Alpaugh ML, Fontana JA, Barsky SH. Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem. 1998;69(1):44–54. doi:10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee WH, Park KY, Zhang L. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res. 2000;91(2):164–173. doi:10.1111/j.1349-7006.2000.tb00928.x
   PubMedGoogle Scholar
• Zhang Z, Wang C-Z, Du G-J, Qi L-W, Calway T, He T-C, Du W, Yuan C-S. Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. Int J Oncol. 2013;43(1):289–296. doi:10.3892/ijo.2013.1946
   PubMed Web of Science ®Google Scholar
• Zheng W, Sun R, Yang L, Zeng X, Xue Y, An R. Daidzein inhibits choriocarcinoma proliferation by arresting cell cycle at G1 phase through suppressing ERK pathway in vitro and in vivo. Oncol Rep. 2017;38(4):2518–2524. doi:10.3892/or.2017.5928
   PubMed Web of Science ®Google Scholar
• Choi EJ, Kim GH. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine. 2008;15(9):683–690. doi:10.1016/j.phymed.2008.04.006
   PubMed Web of Science ®Google Scholar
• Yang ZP, Zhao Y, Huang F, Chen J, Yao YH, et al. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway. WJG. 2015;21(36):10385–10399. doi:10.3748/wjg.v21.i36.10385
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhou R, Kong Y, Wang J, Xia W, Guo J, Liu J, Sun H, Liu K, Yang J, et al. S-equol, a secondary metabolite of natural anticancer isoflavone daidzein, inhibits prostate cancer growth in vitro and in vivo, though activating the Akt/FOXO3a pathway. Curr Cancer Drug Targets. 2016;16(5):455–465. doi:10.2174/1568009616666151207105720
   PubMed Web of Science ®Google Scholar